Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders

Molecular Genetics and Metabolism

Volumn 117, Issue 2, 2016, Pages 186-193

  Ferraz, Maria J ^a   Marques, André R A ^a   Gaspar, Paulo ^b,c,d   Mirzaian, Mina ^e   van Roomen, Cindy ^a   Ottenhoff, Roelof ^a   Alfonso, Pilar ^f   Irún, Pilar ^f   Giraldo, Pilar ^f   Wisse, Patrick ^e   Sá Miranda, Clara ^b,c   Overkleeft, Herman S ^e   Aerts, Johannes M ^a,e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e LEIDEN UNIVERSITY   (Netherlands)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Fabry disease; Gaucher disease; Glycosphingoid bases; Glycosphingolipid; LC MS MS; Mouse models; Niemann Pick type C

Indexed keywords

ALPHA GALACTOSIDASE; CERAMIDE; GALACTOSYLCERAMIDASE; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; GLUCOSYLCERAMIDASE; GLUCOSYLSPHINGOSINE; GLYCOSPHINGOLIPID; GLYCOSYLCERAMIDE; GLYCOSYLSPHINGOSINE; LACTOSYLCERAMIDE; LYSOGLYCOSPHINGOLIPID; PSYCHOSINE; UNCLASSIFIED DRUG; STEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FABRY DISEASE; FEMALE; HEART; HUMAN; KIDNEY; LIPID BLOOD LEVEL; MALE; MOUSE; MOUSE MODEL; MURINE MODEL; NEWBORN; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; CASE CONTROL STUDY; LIPID METABOLISM; LIVER; METABOLISM; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; CASE-CONTROL STUDIES; FEMALE; GLYCOSPHINGOLIPIDS; KIDNEY; LIPID METABOLISM; LIVER; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; NIEMANN-PICK DISEASE, TYPE C; SPLEEN; STEROLS;

EID: 84957838562     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2015.12.006     Document Type: Article

References (60)

1. Thudichum J. A Treatise on the Chemical Constitution of the Brain 1884, Bailliere Tindall and Cox, London.
2. Schulze H., Sandhoff K. Sphingolipids and lysosomal pathologies. Biochim. Biophys. Acta 2014, 1841:799-810.
3. Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D., Cummings C., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997, 277:228-231.
4. Naureckiene S., Sleat D.E., Lackland H., Fensom A., Vanier M.T., Wattiaux R., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000, 290:2298-2301.
5. Miyatake T., Suzuki K. Additional deficiency of psychosine galactosidase in globoid cell leukodystrophy: an implication to enzyme replacement therapy. Birth Defects Orig. Artic. Ser. 1973, 9:136-140.
6. Ferraz M.J., Kallemeijn W.W., Mirzaian M., Herrera Moro D., Marques A., Wisse P., et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim. Biophys. Acta 2014, 1841:811-825.
7. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2812-2817.
8. Dekker N., van Dussen L., Hollak C.E.M., Overkleeft H., Scheij S., Ghauharali K., et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118:e118-e127.
9. Auray-Blais C., Boutin M., Gagnon R., Dupont F.O., Lavoie P., Clarke J.T.R. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal. Chem. 2012, 84:2745-2753.
10. Mirzaian M., Wisse P., Ferraz M.J., Gold H., Donker-Koopman W.E., Verhoek M., et al. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard. Blood Cells Mol. Dis. 2015, 54:307-314.
11. Rolfs A., Giese A.-K., Grittner U., Mascher D., Elstein D., Zimran A., et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 2013, 8.
12. Suzuki K. The twitcher mouse. A model of human globoid cell leukodystrophy (Krabbe's disease). Am. J. Pathol. 1983, 111:394-397.
13. Sakai N., Inui K., Tatsumi N., Fukushima H., Nishigaki T., Taniike M., et al. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J. Neurochem. 1996, 66:1118-1124.
14. Berkovic S.F., Dibbens L.M., Oshlack A., Silver J.D., Katerelos M., Vears D.F., et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-deficiency causes myoclonus epilepsy and glomerulosclerosis. Am. J. Hum. Genet. 2008, 82:673-684.
15. Gamp A.-C., Tanaka Y., Lüllmann-Rauch R., Wittke D., D'Hooge R., De Deyn P.P., et al. LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum. Mol. Genet. 2003, 12:631-646.
16. Enquist I.B., Nilsson E., Ooka A., Månsson J.-E., Olsson K., Ehinger M., et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13819-13824.
17. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., et al. Alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. 1997, 94:2540-2544.
18. Loftus S.K., Morris J.A., Carstea E.D., Gu J.Z., Cummings C., Brown A., et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 1997, 277:232-235.
19. Maue R.A., Burgess R.W., Wang B., Wooley C.M., Seburn K.L., Vanier M.T., et al. A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations. Hum. Mol. Genet. 2012, 21:730-750.
20. Wisse P., Gold H., Mirzaian M., Ferraz M.J., Lutteke G., van den Berg R.J.B.H.N., et al. Synthesis of a panel of carbon-13-labelled (glyco)sphingolipids. Eur. J. Org. Chem. 2015, 2661-2677.
21. Gold H., Mirzaian M., Dekker N., Joao Ferraz M., Lugtenburg J., Codée J.D.C., et al. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin. Chem. 2012, 59:1-10.
22. Dahl M., Doyle A., Olsson K., Månsson J.-E., Marques A.R.A., Mirzaian M., et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol. Ther. 2015, 23:835-844.
23. Groener J.E.M., Poorthuis B.J.H.M., Kuiper S., Helmond M.T.J., Hollak C.E.M., Aerts J.M.F.G. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin. Chem. 2007, 53:742-747.
24. Pentchev P.G., Gal A.E., Booth A.D., Omodeo-Sale F., Fouks J., Neumeyer B.A., et al. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. Biochim. Biophys. Acta 1980, 619:669-679.
25. Salvioli R., Scarpa S., Ciaffoni F., Tatti M., Ramoni C., Vanier M.T., et al. Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C. J. Biol. Chem. 2004, 279:17674-17680.
26. Pavlova E.V., Archer J., Wang S., Dekker N., Aerts J.M., Karlsson S., et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J. Pathol. 2015, 235:113-124.
27. Lombardo E., van Roomen C.P., van Puijvelde G.H., Ottenhoff R., van Eijk M., Aten J., et al. Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism. PLoS One 2012, 7.
28. van Breemen M.J., Rombach S.M., Dekker N., Poorthuis B.J., Linthorst G.E., Zwinderman A.H., et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim. Biophys. Acta 2011, 1812:70-76.
29. Gaspar P., Kallemeijn W.W., Strijland A., Scheij S., Van Eijk M., Aten J., et al. Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis. J. Lipid Res. 2014, 55:138-145.
30. Jiang X., Sidhu R., Porter F.D., Yanjanin N.M., Speak A.O., te Vruchte D.T., et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J. Lipid Res. 2011, 52:1435-1445.
31. Cebolla J.J., De Castro-Orós I., Irún P., Alfonso P., López de Frutos L., Andrade-Campos M., et al. Experience with 7-ketocholesterol and ccl18/parc as surrogated biomarkers in a series of Spanish Niemann-Pick disease type C patients. Mol. Genet. Metab. 2015, 114:S29.
32. Whitfield P.D., Sharp P.C., Taylor R., Meikle P. Quantification of galactosylsphingosine in the twitcher mouse using electrospray ionization-tandem mass spectrometry. J. Lipid Res. 2001, 42:2092-2095.
33. Vedder A.C., Cox-Brinkman J., Hollak C.E.M., Linthorst G.E., Groener J.E.M., Helmond M.T.J., et al. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol. Genet. Metab. 2006, 89:239-244.
34. Germain D.P. Fabry disease. Orphanet J. Rare Dis. 2010, 5:30.
35. Rombach S.M., van den Bogaard B., de Groot E., Groener J.E.M., Poorthuis B.J., Linthorst G.E., et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012, 60:998-1005.
36. Biegstraaten M., Linthorst G.E., van Schaik I.N., Hollak C.E.M. Fabry disease: a rare cause of neuropathic pain. Curr. Pain Headache Rep. 2013, 17:365.
37. Choi L., Vernon J., Kopach O., Minett M.S., Mills K., Clayton P.T., et al. The Fabry disease-associated lipid lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci. Lett. 2015, 594:163-168.
38. Sanchez-Niño M.D., Sanz A.B., Carrasco S., Saleem M.A., Mathieson P.W., Valdivielso J.M., et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant. 2011, 26:1797-1802.
39. Shin Y.-J., Jeon Y.J., Jung N., Park J.-W., Park H.-Y., Jung S.-C. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease. Mol. Med. Rep. 2015, 12:5049-5057.
40. Byeon S.K., Lee J.Y., Lee J.-S., Moon M.H. Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2015, 1381:132-139.
41. Reczek D., Schwake M., Schröder J., Hughes H., Blanz J., Jin X., et al. LIMP-is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007, 131:770-783.
42. Dardis A., Filocamo M., Grossi S., Ciana G., Franceschetti S., Dominissini S., et al. Biochemical and molecular findings in a patient with myoclonic epilepsy due to a mistarget of the beta-glucosidase enzyme. Mol. Genet. Metab. 2009, 97:309-311.
43. Gieselmann V. Lysosomal storage diseases. Biochim. Biophys. Acta 1995, 1270:103-136.
44. Cox T.M., Cachón-González M.B. The cellular pathology of lysosomal diseases. J. Pathol. 2012, 226:241-254.
45. Pavlova E., Wang S., Archer J., Dekker N., Aerts J., Karlsson S., et al. B cell lymphoma and myeloma in murine Gaucher's disease. J. Pathol. 2013, 231:88-97.
46. Igisu H., Suzuki K. Progressive accumulation of toxic metabolite in a genetic leukodystrophy. Science 1984, 224:753-755.
47. White A.B., Givogri M.I., Lopez-Rosas A., Cao H., van Breemen R., Thinakaran G., et al. Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. J. Neurosci. 2009, 29:6068-6077.
48. Zaka M., Wenger D.A. Psychosine-induced apoptosis in a mouse oligodendrocyte progenitor cell line is mediated by caspase activation. Neurosci. Lett. 2004, 358:205-209.
49. Krabbe K. A new familial, infantile form of diffuse brain-sclerosis. Brain 1916, 39:74-114.
50. Pastores G.M. Krabbe disease: an overview. Int. J. Clin. Pharmacol. Ther. 2009, 47(Suppl. 1):S75-S81.
51. Castelvetri L.C., Givogri M.I., Zhu H., Smith B., Lopez-Rosas A., Qiu X., et al. Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol. 2011, 122:35-48.
52. Subramanian K., Balch W.E. NPC1/NPC2 function as a tag team duo to mobilize cholesterol. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15223-15224.
53. Pentchev P.G., Boothe A.D., Kruth H.S., Weintroub H., Stivers J., Brady R.O. A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J. Biol. Chem. 1984, 259:5784-5791.
54. Lloyd-Evans E., Platt F.M. Lipids on trial: the search for the offending metabolite in niemann-pick type C disease. Traffic 2010, 11:419-428.
55. Besley G.T., Moss S.E. Studies on sphingomyelinase and beta-glucosidase activities in Niemann-Pick disease variants. Phosphodiesterase activities measured with natural and artificial substrates. Biochim. Biophys. Acta 1983, 752:54-64.
56. Vanier M.T. Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim. Biophys. Acta 1983, 750:178-184.
57. Welford R.W.D., Garzotti M., Marques Lourenço C., Mengel E., Marquardt T., Reunert J., et al. Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-Pick disease type C in a retrospective study. PLoS One 2014, 9.
58. Bauer P., Balding D.J., Klünemann H.H., Linden D.E.J., Ory D.S., Pineda M., et al. Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study. Hum. Mol. Genet. 2013, 22:4349-4356.
59. Giese A.-K., Mascher H., Grittner U., Eichler S., Kramp G., Lukas J., et al. A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease. Orphanet J. Rare Dis. 2015, 10:78.
60. Porter F.D., Scherrer D.E., Lanier M.H., Langmade S.J., Molugu V., Gale S.E., et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci. Transl. Med. 2010, 2:56ra81.